| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Leelamine HCl targets multiple cellular pathways and proteins. It is a cannabinoid type 1 (CB1) receptor agonist, an inhibitor of SREBP1-regulated fatty acid/lipid synthesis, and an inhibitor of pyruvate dehydrogenase kinase (PDK) with an IC50 of 9.5 µM. It also acts as an inhibitor of intracellular cholesterol transport and an inducer of cytochrome P450 2B5. It has been reported to inhibit the androgen receptor (AR). This multi-target profile contributes to its diverse biological effects, including the induction of apoptosis in cancer cells.
|
|---|---|
| ln Vitro |
In vitro, Leelamine HCl demonstrates potent anticancer activity against various cancer cell lines. It induces apoptosis in breast cancer, melanoma, and prostate cancer cells. In prostate cancer cells, it inhibits SREBP1-regulated fatty acid and lipid synthesis independent of androgen receptor status. The compound causes cancer cell death through the inhibition of intracellular cholesterol transport. It also induces apoptosis in K562/A02 leukemia cells. However, detailed IC50 values for these activities are not extensively reported in the available literature.
|
| ln Vivo |
In vivo, Leelamine HCl has demonstrated efficacy in suppressing the growth of 22Rv1 xenograft tumors in mice. This confirms its potential as an anticancer agent. The compound's mechanism of action in vivo is attributed to its ability to inhibit cholesterol transport and induce apoptosis in cancer cells. However, detailed in vivo efficacy data, including dosing regimens and pharmacokinetic-pharmacodynamic relationships, are not extensively reported in the available literature.
|
| Enzyme Assay |
In vitro enzyme assays for Leelamine HCl include measuring its inhibitory activity against pyruvate dehydrogenase kinase (PDK). The enzyme is incubated with a substrate in the presence of varying concentrations of the compound, and the kinase activity is measured. The compound's ability to inhibit SREBP1-regulated fatty acid/lipid synthesis can also be assessed in cell-based assays by measuring the expression of SREBP1 target genes or lipid accumulation.
|
| Cell Assay |
Cellular assays for Leelamine HCl are performed in various cancer cell lines to assess its cytotoxic and apoptotic effects. Cells are treated with various concentrations of the compound, and cell viability is assessed using assays such as MTT or resazurin reduction. Apoptosis is measured by flow cytometry using Annexin V staining or by measuring caspase activity. The compound's effects on cholesterol transport are assessed by measuring cholesterol accumulation in lysosomes using fluorescent cholesterol analogs.
|
| Animal Protocol |
In vivo animal studies with Leelamine HCl have been performed in mouse xenograft models. Human cancer cells (e.g., 22Rv1 prostate cancer cells) are implanted subcutaneously into immunodeficient mice. Once tumors are established, Leelamine HCl is administered, typically via intraperitoneal injection. Tumor growth is monitored over time, and at the end of the study, tumors are excised and analyzed for apoptosis and other biomarkers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Leelamine HCl are not extensively reported. The compound is a tricyclic diterpene with a molecular weight of 321.9 (as the HCl salt). It is expected to be lipophilic and cell-permeable. However, detailed pharmacokinetic parameters such as absorption, distribution, metabolism, excretion, half-life, and bioavailability are not available in the literature for this research compound.
|
| Toxicity/Toxicokinetics |
Leelamine HCl has been studied in cell-based assays and in animal models and appears to have a manageable safety profile at therapeutic doses. However, comprehensive toxicology data for this compound are not extensively reported. The compound is classified as a research-use-only chemical and is not intended for human consumption. Specific toxicological data, including acute toxicity, genotoxicity, and target organ effects, are not reported in the available literature.
|
| References |
|
| Additional Infomation |
Leelamine HCl is a research-grade compound not approved for clinical use. Its primary applications are in cancer research and lipid metabolism studies. The compound is used to study the role of cholesterol transport in cancer cell survival, the function of CB1 receptors, and the regulation of lipid synthesis. Its multi-target profile makes it a valuable tool for investigating the complex interplay between lipid metabolism, signaling pathways, and cancer cell biology.
|
| Molecular Formula |
C20H32CLN
|
|---|---|
| Molecular Weight |
321.933
|
| Exact Mass |
321.222
|
| CAS # |
16496-99-4
|
| Related CAS # |
Leelamine;1446-61-3
|
| PubChem CID |
16759156
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.281
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
376
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC(C)C1=CC2=C(C=C1)[C@]3(CCC[C@@]([C@@H]3CC2)(C)CN)C.Cl
|
| InChi Key |
CVPQLGCAWUAYPF-WFBUOHSLSA-N
|
| InChi Code |
InChI=1S/C20H31N.ClH/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4;/h6,8,12,14,18H,5,7,9-11,13,21H2,1-4H3;1H/t18-,19-,20+;/m0./s1
|
| Chemical Name |
((1R,4aS,10aR)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)methanamine hydrochloride
|
| Synonyms |
Leelamine hydrochlorideDehydroabietylamine HCl Leelamine HCl Leelamine NSC 2955 NSC2955NSC-2955
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~77.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1063 mL | 15.5313 mL | 31.0627 mL | |
| 5 mM | 0.6213 mL | 3.1063 mL | 6.2125 mL | |
| 10 mM | 0.3106 mL | 1.5531 mL | 3.1063 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
